{"created":"2023-05-15T14:36:18.174649+00:00","id":46736,"links":{},"metadata":{"_buckets":{"deposit":"59c14367-06fa-4188-b58c-0ba3ec69c8ce"},"_deposit":{"created_by":1,"id":"46736","owners":[1],"pid":{"revision_id":0,"type":"depid","value":"46736"},"status":"published"},"_oai":{"id":"oai:repo.qst.go.jp:00046736","sets":["1"]},"author_link":["466053","466056","466061","466063","466057","466060","466055","466065","466064","466054","466059","466062","466058"],"item_8_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2013-12","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"8","bibliographicPageEnd":"878","bibliographicPageStart":"872","bibliographicVolumeNumber":"39","bibliographic_titles":[{"bibliographic_title":"Cancer Treatment Reviews"}]}]},"item_8_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"The prognosis of high-risk prostate cancer is poor with a high mortality rate. The Radiation Therapy Oncology Group (RTOG) has performed dose-escalation studies of external beam radiation therapy (EBRT) and has developed high-precision radiation therapy (RT) methods such as intensity-modulated RT, carbon ion therapy, and proton beam therapy. High-dose rate brachytherapy (HDR-BT) is also studied as an option for high-risk prostate cancer treatment. Past clinical trials have suggested that the local control rate of high-risk prostate cancer improves with total EBRT dose, even for doses >70 Gy. Several randomized controlled trials, including RTOG 94-06, have shown significantly better prognoses with higher doses (>75 Gy) than with lower doses (<70 Gy). A proton beam therapy trial (PROG 95&#8211;09) also showed similar results. A phase II clinical trial (National Institute for Radiological Sciences, Japan; trial 9904) showed that carbon ion therapy resulted in very good biochemical recurrence-free survival rates among high-risk prostate cancer patients, demonstrating particle therapy to be a valid treatment option. RTOG 86-10 showed that short-term neo-adjuvant hormonal therapy (HT) was inadequate for high-risk prostate cancer but effective for intermediate-risk prostate cancer, whereas RTOG 92-02 and the European Organisation for Research and Treatment of Cancer (EORTC) 22863 showed significant improvements in the prognosis of high-risk groups receiving long-term (>2 years) HT combined with definitive RT. Further studies are warranted to elucidate optimal irradiation doses, HT treatment durations, and combination therapy schedules.","subitem_description_type":"Abstract"}]},"item_8_relation_14":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type_id":{"subitem_relation_type_id_text":"10.1016/j.ctrv.2013.04.003","subitem_relation_type_select":"DOI"}}]},"item_8_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"0305-7372","subitem_source_identifier_type":"ISSN"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"metadata only access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_14cb"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Nomiya, Takuma"}],"nameIdentifiers":[{"nameIdentifier":"466053","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Tsuji, Hiroshi"}],"nameIdentifiers":[{"nameIdentifier":"466054","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Toyama, Shingo"}],"nameIdentifiers":[{"nameIdentifier":"466055","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Maruyama, Katsuya"}],"nameIdentifiers":[{"nameIdentifier":"466056","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Nemoto, Kenji"}],"nameIdentifiers":[{"nameIdentifier":"466057","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Tsujii, Hirohiko"}],"nameIdentifiers":[{"nameIdentifier":"466058","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Kamada, Tadashi"}],"nameIdentifiers":[{"nameIdentifier":"466059","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"野宮 琢磨","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"466060","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"辻 比呂志","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"466061","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"戸山 真吾","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"466062","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"丸山 克也","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"466063","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"辻井 博彦","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"466064","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"鎌田 正","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"466065","nameIdentifierScheme":"WEKO"}]}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Management of high-risk prostate cancer: Radiation therapy and hormonal therapy","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Management of high-risk prostate cancer: Radiation therapy and hormonal therapy"}]},"item_type_id":"8","owner":"1","path":["1"],"pubdate":{"attribute_name":"公開日","attribute_value":"2014-03-05"},"publish_date":"2014-03-05","publish_status":"0","recid":"46736","relation_version_is_last":true,"title":["Management of high-risk prostate cancer: Radiation therapy and hormonal therapy"],"weko_creator_id":"1","weko_shared_id":-1},"updated":"2023-05-15T23:48:14.332754+00:00"}